Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.


Journal Article

Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA-LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.

Full Text

Duke Authors

Cited Authors

  • Pardi, N; Hogan, MJ; Pelc, RS; Muramatsu, H; Andersen, H; DeMaso, CR; Dowd, KA; Sutherland, LL; Scearce, RM; Parks, R; Wagner, W; Granados, A; Greenhouse, J; Walker, M; Willis, E; Yu, J-S; McGee, CE; Sempowski, GD; Mui, BL; Tam, YK; Huang, Y-J; Vanlandingham, D; Holmes, VM; Balachandran, H; Sahu, S; Lifton, M; Higgs, S; Hensley, SE; Madden, TD; Hope, MJ; Karikó, K; Santra, S; Graham, BS; Lewis, MG; Pierson, TC; Haynes, BF; Weissman, D

Published Date

  • March 9, 2017

Published In

Volume / Issue

  • 543 / 7644

Start / End Page

  • 248 - 251

PubMed ID

  • 28151488

Pubmed Central ID

  • 28151488

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

Digital Object Identifier (DOI)

  • 10.1038/nature21428


  • eng

Conference Location

  • England